supp.fit

Carnitine: study protocols

21 study groups say how much Carnitine participants took a day. These are the doses the studies gave. They are not a recommendation.

Carnitine: what the research found →

Dose per serving from products

25 products in our catalogue print how much Carnitine a serving holds.

Most common: 10 mg to 25 mg, 36% of 25 products.

Dose per servingProducts
5 mg or less
2
5 mg to 10 mg
3
10 mg to 25 mg
9
25 mg to 50 mg
0
50 mg to 100 mg
1
100 mg to 250 mg
1
250 mg to 500 mg
6
500 mg to 1 g
0
1 g to 2.5 g
3

Dose per serving from research

19 study groups in 15 studies say how much Carnitine participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 53% of 19 study groups.

Daily doseStudy groups
1 mg or less
1
1 mg to 2.5 mg
1
2.5 mg to 5 mg
0
5 mg to 10 mg
0
10 mg to 25 mg
0
25 mg to 50 mg
0
50 mg to 100 mg
1
100 mg to 250 mg
1
250 mg to 500 mg
0
500 mg to 1 g
5
1 g to 2.5 g
10

Commonly used together

4 of 21 study groups took Carnitine with something else, but nothing that 3 or more different studies gave.

21 study groups

Study
Carnitine supplementation in diphtheria
1992 · DL-carnitine · Children with diphtheria
100 mg/kg4 days327
Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial
2014 · carnitine group · Patients receiving antituberculosis treatment; age and sex not specified
2 g4 weeks54
Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study
1995 · propionyl-L-carnitine · Patients with intermittent claudication
1 g24 weeks118
Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome
2004 · propionyl-L-carnitine group · people with chronic fatigue syndrome; age and sex not reported
2 g24 weeks30
Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
2016 · carnitine supplements · Overweight women diagnosed with PCOS
250 mg12 weeks30
Propionyl carnitine in stable effort angina
1990 · propionyl carnitine (PC) · Men aged 37–70 with typical stable effort angina
1.5 g30 days18
Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease
2002 · Verapamil plus propionyl-L-carnitine (second study) · Men with resistant Peyronie's disease whose disease progressed despite previous therapy
2 g90 days15
Effects of L- and DL-carnitine on patients with impaired exercise tolerance
1995 · DL-carnitine treatment group · Adults with cardiac disease and impaired exercise tolerance; age range and sex not reported
900 mg2 weeks10
Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease
2002 · Verapamil plus propionyl-L-carnitine (first study) · Men with advanced Peyronie's disease
2 g90 days—
Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome
2004 · acetyl-L-carnitine plus propionyl-L-carnitine group · people with chronic fatigue syndrome; age and sex not reported
2 g24 weeks30
Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging
2004 · Group 2 · Men aged 60–74 with symptoms associated with male aging
2 g26 weeks—
Body mass index and age correlate with antioxidant supplementation effects on sperm quality: Post hoc analyses from a double-blind placebo-controlled trial
2020 · supplementation group · Men aged 18–50 with oligo- and/or astheno- and/or teratozoospermia, with or without untreated varicocele
1.5 g26 weeks52
Carnitine supplementation in premature neonates: effect on plasma and red blood cell total carnitine concentrations, nutrition parameters and morbidity
2006 · carnitine supplementation · Premature neonates; mean gestational age 27 ± 2 weeks and mean birthweight 976 ± 259 g
20 mg/kg8 weeks16
Plasma pharmacokinetics and gastrointestinal transit of a new propionyl-L-carnitine controlled release formulation
2011 · 500 mg propionyl-L-carnitine group · Healthy volunteers; age and sex not reported
1 g7 days—
Plasma pharmacokinetics and gastrointestinal transit of a new propionyl-L-carnitine controlled release formulation
2011 · 1000 mg propionyl-L-carnitine group · Healthy volunteers; age and sex not reported
2 g7 days—
Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial
2015 · carnitine-orotate complex · Adults with type 2 diabetes and nonalcoholic fatty liver disease
2.47 g12 weeks39
Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study
2014 · Metformin and carnitine-orotate complex · Drug-naïve patients with impaired glucose metabolism and fatty liver; age and sex not specified
900 mg12 weeks26
Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria
2018 · AA-MFs · Adolescents and adults with early-treated classical or variant phenylketonuria on a low-phenylalanine diet
58.6 mg3 weeks—
Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria
2018 · GMP-MFs · Adolescents and adults with early-treated classical or variant phenylketonuria on a low-phenylalanine diet
300 mcg3 weeks—
Effects of Chromium and Carnitine Co-supplementation on Body Weight and Metabolic Profiles in Overweight and Obese Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial
2020 · supplement group · Overweight women with polycystic ovary syndrome (PCOS)
1 g12 weeks27
Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure
1998 · propionyl-L-carnitine group · Patients with chronic congestive heart failure, NYHA class II–III
1.5 mg30 days—